Narrative review / 2017
Intragastric balloon treatment yielded a 6-month control-subtracted weight loss of 5.5–5.6% but carried a 10.5% serious adverse event rate.
This review analyzed eight RCTs (five with 6-month duration) evaluating intragastric balloon (IGB) devices for obesity. Efficacy at 6 months showed a pooled weighted-mean %TBWL of 9.7% and a control-subtracted %TBWL of 5.6% (or 9.3 ± 5.7% and 5.5 ± 7.8% when excluding one study lacking SDs). Weight loss was lower than bariatric surgery and slightly below the drug Qsymia (placebo-subtracted %TBWL of ~6.6%). The weighted mean incidence of serious adverse events was 10.5%, with pooled adverse events reported at 28.2% across six studies, leading authors to conclude that modest efficacy and complications make widespread adoption unlikely.
- Study type
- Review of randomized controlled trials
- Who was studied
- Patients with obesity in 8 RCTs (2006-present)
- What was measured
- Percentage total body weight loss (%TBWL) and adverse events
THE PAPER
Intragastric Balloon Treatment for Obesity: Review of Recent Studies.
Tate CM, Geliebter A. Adv Ther, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.